Remnant Cholesterol and Its Visit-to-Visit Variability Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes: Findings From the ACCORD Cohort
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Remnant cholesterol (remnant-C) predicts atherosclerotic cardiovascular disease, regardless of LDL-cholesterol (LDL-C) levels. This study assessed the associations between remnant-C and cardiovascular outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS: This post hoc analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial used patient (type 2 diabetes >3 months) remnant-C and major adverse cardiovascular event (MACE) data from the study database. The associations between remnant-C and MACEs were evaluated using Cox proportional hazards regression analyses. We examined the relative MACE risk in remnant-C versus LDL-C discordant/concordant groups using clinically relevant LDL-C targets by discordance analyses. RESULTS: The baseline analysis included 10,196 participants, with further visit-to-visit variability analysis including 9,650 participants. During follow-up (median, 8.8 years), 1,815 patients (17.8%) developed MACEs. After adjusting for traditional cardiovascular risk factors, each 1-SD increase in remnant-C was associated with a 7% higher MACE risk (hazard ratio [HR] 1.07, 95% CI 1.02–1.12, P = 0.004). In the fully adjusted model, the visit-to-visit remnant-C variability calculated using logSD (HR 1.41, 95% CI 1.18–1.69, P < 0.001) and logARV (HR 1.45, 95% CI 1.22–1.73, P < 0.001) was associated with MACEs. Residual lipid risk (remnant-C ≥31 mg/dL) recognized individuals at a higher MACE risk, regardless of LDL-C concentrations. Within each LDL-C subgroup (>100 or ≤100 mg/dL), high baseline remnant-C was associated with a higher MACE risk (HR 1.37, 95% CI 1.09–1.73, P = 0.007; HR 1.22, 95% CI 1.04–1.41, P = 0.015, respectively). CONCLUSIONS: Remnant-C levels were associated with MACEs in patients with type 2 diabetes independent of LDL-C, and visit-to-visit remnant-C variability helped identify those with higher cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“Notably, TG-lowering therapy in type 2 diabetes failed to reduce the rate of coronary heart disease events in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) (2) and Fenofibrate Intervention and Event Lowering in Diabetes (23) trials.”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Body Fat Distribution and Risk of Cardiovascular Disease: An Update
Després, J.-P. (2012) · Circulation · doi:10.1161/circulationaha.111.067264 · Cited by 1,481
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716 · cited 1×
“Furthermore, genetic studies strongly suggest that a higher remnant-C level is a causal risk factor for coronary artery disease (33,34).”
BackgroundRemnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease
Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Estruch, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.008 · Cited by 540 · cited 3×
“Additionally, a large observational study showed that high levels of remnant-C, but not LDL-C, are associated with cardiovascular outcomes in overweight or obese individuals (21) and in atherosclerotic CVD-free individuals (22).”
BackgroundJørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: A primary prevention study
Quispe, R., Martin, S. S., Michos, E. D., Lamba, I., Blumenthal, R. S., Saeed, A., Lima, J., Puri, R., Nomura, S., Tsai, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab432 · Cited by 441
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440 · cited 1×
“Furthermore, genetic studies strongly suggest that a higher remnant-C level is a causal risk factor for coronary artery disease (33,34).”
BackgroundSchwartz, G. G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., Mundl, H., & Olsson, A. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.544 · Cited by 272
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.002 · Cited by 233
Jepsen, A.-M. K., Langsted, A., Varbo, A., Bang, L. E., Kamstrup, P. R., & Nordestgaard, B. G. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.253757 · Cited by 218 · cited 1×
“within the entire cohort, as previously described (20).”
Twickler, T. B., Dallinga-Thie, G. M., Cohn, J. S., & Chapman, M. J. (2004) · Circulation · doi:10.1161/01.cir.0000125278.58527.f3 · Cited by 201 · cited 4×
“Since HDL-C–raising therapies have failed to reduce atherosclerotic cardiovascular events (9,10), the research focus has shifted to TG-rich lipoproteins (TRLs), which are composed of chylomicron remnants, VLDL-C, and intermediatedensity lipoprotein.”
BackgroundInfluentialVallejo-Vaz, A. J., Fayyad, R., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J., Melamed, S., Barter, P., Waters, D. D., & Ray, K. K. (2018) · Circulation · doi:10.1161/circulationaha.117.032318 · Cited by 187 · cited 2×
“From these data, we could postulate that treatment of residual risk, measured as remnant-C, was likely more beneficial than further reduction of LDL-C levels in high-risk individuals already treated with moderateor high-dose statins (19,36,37).”
BackgroundLawler, P. R., Akinkuolie, A. O., Chu, A. Y., Shah, S. H., Kraus, W. E., Craig, D., Padmanabhan, L., Glynn, R. J., Ridker, P. M., Chasman, D. I., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005549 · Cited by 145
Lawler, P. R., Akinkuolie, A. O., Ridker, P. M., Sniderman, A. D., Buring, J. E., Glynn, R. J., Chasman, D. I., & Mora, S. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.264515 · Cited by 104 · cited 1×
“In addition, previous studies used the aforementioned methods for determining remnantC cutoffs corresponding to three different LDL-C values (70, 100, and 130 mg/dL) for discordance analyses (22,31).”
MethodFukushima, H., Sugiyama, S., Honda, O., Koide, S., Nakamura, S., Sakamoto, T., Yoshimura, M., Ogawa, H., Fujioka, D., & Kugiyama, K. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.09.074 · Cited by 91
Lévesque, V., Poirier, P., Després, J.-P., & Alméras, N. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.08.008 · Cited by 25
Cited by
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404143 · Cited by 210
Wang, J., Jin, R., Jin, X., Wu, Z., Zhang, H., Han, Z., Xu, Z., Liu, Y., Zhao, X., Guo, X., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029352 · Cited by 21
Jia, Y.-P., Wang, J.-M., Lyu, J.-Q., Yang, H.-H., Miao, M.-Y., Wang, X., Wan, Z.-X., Zheng, Y., Qin, L.-Q., Li, F.-R., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100653 · Cited by 10
Metadata
- Authors
- Fu, L., Tai, S., Sun, J., Zhang, N., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-07-14
- Volume
- 45
- Issue
- 9
- Pages
- 2136-2143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4285389822
- Cited by
- 77
- References
- 28
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.